These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21295363)

  • 21. Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients.
    Egede R; Jensen LO; Hansen HS; Antonsen L; Hansen KN; Junker A; Thayssen P
    Int J Cardiol; 2012 Jul; 158(3):376-9. PubMed ID: 21349594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.
    Calza L; Vanino E; Salvadori C; Manfredi R; Colangeli V; Cascavilla A; Di Bari MA; Motta R; Viale P
    HIV Clin Trials; 2014; 15(1):1-13. PubMed ID: 24518210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical study of the month: ASTEROID: regression of coronary atherosclerosis with rosuvastatin at a maximal daily dose of 40 mg].
    Scheen AJ
    Rev Med Liege; 2006 Apr; 61(4):267-72. PubMed ID: 16789616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Arterioscler Thromb Vasc Biol; 2014 Nov; 34(11):2465-72. PubMed ID: 25212234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN).
    Nicholls SJ; Borgman M; Nissen SE; Raichlen JS; Ballantyne C; Barter P; Chapman MJ; Erbel R; Libby P
    Curr Med Res Opin; 2011 Jun; 27(6):1119-29. PubMed ID: 21446892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.
    Puri R; Nissen SE; Menon V; Shao M; Hsu A; Bakris GL; Kastelein JJ; Williams B; Armbrecht J; Brunel P; Kataoka Y; Nicholls SJ
    Atherosclerosis; 2015 Dec; 243(2):553-9. PubMed ID: 26523993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensive lipid-lowering therapy with rosuvastatin stabilizes lipid-rich coronary plaques. -Evaluation using dual-source computed tomography.-.
    Soeda T; Uemura S; Okayama S; Kawakami R; Sugawara Y; Nakagawa H; Matsumoto T; Sung JH; Nishida T; Senoo A; Somekawa S; Takeda Y; Ishigami K; Kawata H; Horii M; Saito Y
    Circ J; 2011; 75(11):2621-7. PubMed ID: 21821963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness--Justification for Atherosclerosis Regression Treatment (JART) extension study.
    Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yokoi H; Yoshida M;
    Circ J; 2013; 77(6):1526-33. PubMed ID: 23486191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂.
    Rizos CV; Liberopoulos EN; Tellis CC; Florentin M; Elisaf MS; Tselepis AD
    Metab Syndr Relat Disord; 2011 Jun; 9(3):217-23. PubMed ID: 21352079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke.
    Ueno Y; Yamashiro K; Tanaka Y; Watanabe M; Shimada Y; Kuroki T; Miyamoto N; Daimon M; Tanaka R; Miyauchi K; Daida H; Hattori N; Urabe T
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):79-85. PubMed ID: 24072337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between intravascular ultrasound-derived percent total atheroma volume and fractional flow reserve in the intermediate stenosis of proximal or middle left anterior descending coronary artery.
    Jin XJ; Tahk SJ; Yang HM; Lim HS; Yoon MH; Choi SY; Choi BJ; Hwang GS; Seo KW; Shin JS; Lee YH; Choi YW; Park SJ; Park JS; Shin JH
    Int J Cardiol; 2015 Apr; 185():56-61. PubMed ID: 25791091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
    Ballantyne CM; Weiss R; Moccetti T; Vogt A; Eber B; Sosef F; Duffield E;
    Am J Cardiol; 2007 Mar; 99(5):673-80. PubMed ID: 17317370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
    Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
    Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization.
    Thondapu V; Kurihara O; Yonetsu T; Russo M; Kim HO; Lee H; Soeda T; Minami Y; Jang IK
    Am J Cardiol; 2019 May; 123(10):1565-1571. PubMed ID: 30851941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia.
    Gliozzi M; Walker R; Muscoli S; Vitale C; Gratteri S; Carresi C; Musolino V; Russo V; Janda E; Ragusa S; Aloe A; Palma E; Muscoli C; Romeo F; Mollace V
    Int J Cardiol; 2013 Dec; 170(2):140-5. PubMed ID: 24239156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of baseline plaque components on plaque progression in nonintervened coronary segments in patients with angina pectoris on rosuvastatin 10 mg/day.
    Hong YJ; Jeong MH; Choi YH; Ma EH; Ko JS; Lee MG; Park KH; Sim DS; Yoon NS; Youn HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    Am J Cardiol; 2010 Nov; 106(9):1241-7. PubMed ID: 21029819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
    Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
    Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of statins on serial coronary calcification during atheroma progression and regression.
    Puri R; Nicholls SJ; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nissen SE
    J Am Coll Cardiol; 2015 Apr; 65(13):1273-1282. PubMed ID: 25835438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.
    Florentin M; Liberopoulos EN; Rizos CV; Kei AA; Liamis G; Kostapanos MS; Elisaf MS
    Metab Syndr Relat Disord; 2013 Jun; 11(3):152-6. PubMed ID: 23170931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.